Literature DB >> 16759710

Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders.

Schahram Akbarian1, Hsien-Sung Huang.   

Abstract

The 67 and 65 kDa isoforms of glutamic acid decarboxylase, the key enzymes for GABA biosynthesis, are expressed at altered levels in postmortem brain of subjects diagnosed with schizophrenia and related disorders, including autism and bipolar illness. The predominant finding is a decrease in GAD67 mRNA levels, affecting multiple brain regions, including prefrontal and temporal cortex. Postmortem studies, in conjunction with animal models, identified several mechanisms that contribute to the dysregulation of GAD67 in cerebral cortex. These include disordered connectivity formation during development, abnormal expression of Reelin and neural cell adhesion molecule (NCAM) glycoproteins, defects in neurotrophin signaling and alterations in dopaminergic and glutamatergic neurotransmission. These mechanisms are likely to operate in conjunction with genetic risk factors for psychosis, including sequence polymorphisms residing in the promoter of GAD1 (2q31), the gene encoding GAD67. We propose an integrative model, with multiple molecular and cellular mechanisms contributing to transcriptional dysregulation of GAD67 and cortical dysfunction in psychosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16759710     DOI: 10.1016/j.brainresrev.2006.04.001

Source DB:  PubMed          Journal:  Brain Res Rev        ISSN: 0165-0173


  164 in total

Review 1.  GABAergic interneuron origin of schizophrenia pathophysiology.

Authors:  Kazu Nakazawa; Veronika Zsiros; Zhihong Jiang; Kazuhito Nakao; Stefan Kolata; Shuqin Zhang; Juan E Belforte
Journal:  Neuropharmacology       Date:  2011-01-26       Impact factor: 5.250

2.  Epigenetics in the human brain.

Authors:  Isaac Houston; Cyril J Peter; Amanda Mitchell; Juerg Straubhaar; Evgeny Rogaev; Schahram Akbarian
Journal:  Neuropsychopharmacology       Date:  2012-05-30       Impact factor: 7.853

Review 3.  The environment and susceptibility to schizophrenia.

Authors:  Alan S Brown
Journal:  Prog Neurobiol       Date:  2010-10-16       Impact factor: 11.685

Review 4.  Neurodevelopmental animal models of schizophrenia: role in novel drug discovery and development.

Authors:  Christina Wilson; Alvin V Terry
Journal:  Clin Schizophr Relat Psychoses       Date:  2010-07

Review 5.  Cell and receptor type-specific alterations in markers of GABA neurotransmission in the prefrontal cortex of subjects with schizophrenia.

Authors:  David A Lewis; Takanori Hashimoto; Harvey M Morris
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

6.  Synaptic abnormalities and cytoplasmic glutamate receptor aggregates in contactin associated protein-like 2/Caspr2 knockout neurons.

Authors:  Olga Varea; Maria Dolores Martin-de-Saavedra; Katherine J Kopeikina; Britta Schürmann; Hunter J Fleming; Jessica M Fawcett-Patel; Anthony Bach; Seil Jang; Elior Peles; Eunjoon Kim; Peter Penzes
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-27       Impact factor: 11.205

7.  Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia.

Authors:  T Hashimoto; D Arion; T Unger; J G Maldonado-Avilés; H M Morris; D W Volk; K Mirnics; D A Lewis
Journal:  Mol Psychiatry       Date:  2007-05-01       Impact factor: 15.992

Review 8.  Epigenetic regulation in human brain-focus on histone lysine methylation.

Authors:  Schahram Akbarian; Hsien-Sung Huang
Journal:  Biol Psychiatry       Date:  2008-09-24       Impact factor: 13.382

9.  Down-regulated GABAergic expression in the olfactory bulb layers of the mouse deficient in monoamine oxidase B and administered with amphetamine.

Authors:  Hsiang-Shu Yin; Kevin Chen; Jean C Shih; Tai-Wei Tien
Journal:  Cell Mol Neurobiol       Date:  2009-11-10       Impact factor: 5.046

Review 10.  Evolution in health and medicine Sackler colloquium: Comparative genomics of autism and schizophrenia.

Authors:  Bernard Crespi; Philip Stead; Michael Elliot
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.